Fish oil for prevention: keep VITAL’s main result in view

The primary prevention question had a restrained answer

Routine fish-oil supplementation did not significantly reduce VITAL's primary cardiovascular-event outcome or invasive cancer. That is the starting point for interpreting its more encouraging myocardial-infarction result. A trial can contain an informative secondary signal while remaining neutral on the main question it was designed to answer. A consumer deciding whether to begin a supplement needs both parts of that account.

Primary prevention also has a specific meaning here: trying to prevent a first major event in people without the relevant established disease at enrollment. It differs from treatment after an event or treatment of a particular lipid disorder. Putting all omega-3 trials under one fish-oil headline obscures the product, dose and patient group that produced each result.

VITAL specified the capsule and the population

VITAL randomized 25,871 US adults, men aged at least 50 and women at least 55, using a factorial design that also tested vitamin D. The fish-oil arm used one gram daily containing 840 milligrams of marine omega-3s: 460 milligrams EPA and 380 milligrams DHA. During median follow-up of 5.3 years, major cardiovascular events occurred in 386 assigned fish oil and 419 assigned placebo, hazard ratio 0.92 with a 95% confidence interval from 0.80 to 1.06. Invasive cancers numbered 820 and 797. ^[1]

The interval is important. The cardiovascular comparison did not establish a reduction, and the cancer result did not establish prevention either. The counts should not be presented as proof of benefit simply because one group had fewer cardiovascular events. Random variation remains compatible with the estimated effect, which is why the full comparison matters more than subtracting the numbers.

A food-pattern intervention asks a different prevention question; compare the PREDIMED dietary-pattern evidence.

The secondary signal needs its original label

VITAL's myocardial-infarction hazard ratio was 0.72, while stroke and cardiovascular-death comparisons were not significantly favorable. Average self-reported adherence, defined as taking at least two thirds of study capsules, was about 82%; questionnaire response averaged 93%. No excess serious bleeding or other serious adverse events was observed. ^[1] These findings describe this dose and setting. They cannot establish that taking more fish oil would produce a larger benefit or the same safety profile.

A secondary outcome can motivate more focused research. It should not silently replace the primary endpoint when a supplement advertisement summarizes the trial. Likewise, an analysis in a subgroup should retain its exploratory status when the overall comparison is neutral. The sensible reading is neither that every possible benefit has been disproved nor that the favorable slice proves a recommendation for everyone.

ASCEND did not find a clear benefit in diabetes

ASCEND randomized 15,480 people with diabetes but no evident atherosclerotic cardiovascular disease to a one-gram omega-3 capsule or matching olive-oil placebo daily. Over mean follow-up of 7.4 years, with 76% adherence, serious vascular events occurred in 689 participants, or 8.9%, versus 712, or 9.2%. The rate ratio was 0.97, with a 95% confidence interval from 0.87 to 1.08. Nonfatal serious adverse-event rates did not differ significantly. ^[2]

This population had a different risk profile from a general wellness shopper, yet the comparison was still not significantly favorable. The absolute event proportions help keep the result proportionate. Calling the trial a failure of all dietary fish would be another overreach: it tested supplementation against placebo, not replacing a particular food with fish as part of an eating pattern.

A higher dose did not solve the question automatically

STRENGTH enrolled 13,078 statin-treated participants at high cardiovascular risk with elevated triglycerides and low HDL cholesterol. It tested four grams daily of an EPA/DHA carboxylic-acid formulation versus corn oil on top of usual treatment. The trial stopped early for a low probability of benefit. Primary events occurred in 12.0% versus 12.2%, hazard ratio 0.99; gastrointestinal adverse events were more frequent at 24.7% versus 14.7%. Primary outcome status was obtained for 96.6% of participants. New-onset atrial fibrillation, a prespecified tertiary endpoint, occurred in 144 participants (2.2%) versus 86 (1.3%), hazard ratio 1.69 with a 95% confidence interval of 1.29 to 2.21. ^[3]

That result does not make the tested prescription-like formulation equivalent to every retail bottle. It does show why a bigger daily number cannot be assumed to improve the benefit-risk balance. Form, comparator, concurrent care and the target population all belong in the interpretation. Substituting a different supplement for a clinician's specified treatment is not a conclusion supported by comparing these headlines.

The intervention also sat on top of background treatment rather than replacing it. That makes the negative result particularly relevant to claims that a supplement automatically improves an otherwise established cardiovascular plan. A reader should not infer that changing an effective prescribed therapy would improve matters, nor that taking a retail product without that background care recreates the trial. The comparison must travel with the concurrent treatment, not just the capsule dose.

Keep product quality separate from prevention

A lot certificate, clear EPA/DHA label and usable serving size can make a supplement easier to buy responsibly. They do not answer whether the supplement improves a clinical outcome for its purchaser. The prevention question should come before brand selection. Otherwise a high-quality bottle can become an expensive answer to a question that has not been defined.

For a general reader, these trials argue against assuming routine fish oil is necessary insurance against cardiovascular disease or cancer. Someone with a specific clinical indication should discuss that indication and the exact formulation rather than treat this article as advice to stop prescribed treatment. For everyone else, an affordable food pattern, appropriate risk assessment and follow-up are separate decisions that a capsule should not displace. Judge the purchase by the purpose the evidence actually supports.

For serving sizes, lot information and purchasing commitments, see Nordic Naturals Ultimate Omega.